Corrections log
When a fact on this site is wrong, we fix it on the page, update the review date, and list it here. Status changes that follow an FDA action are updates, not corrections, and are tracked on the FDA status tracker.
Last updated Oct 25, 2026
How to report an error
Email hello@peptidesorted.com with the page URL, the sentence in question, and the source you believe is correct. A named reviewer checks it against the primary source. If it is wrong, the page is fixed within two business days for a health fact and a week for anything else.
What counts as a correction
- A number, date, dose, status or citation that did not match its source when published.
- A source link that pointed to the wrong document.
- A statement the cited source did not support.
Rewording for clarity, new sections and scheduled re-reviews are not listed. FDA status changes are recorded on the FDA status tracker.
The log
| Date | Page | What changed |
|---|---|---|
| Nov 2, 2026 | KPV, GHK-Cu and MOTS-c pages | Removed animal-to-human dose conversions and per-dose unit tables that matched doses sold online. The site does not give human doses for unapproved peptides. (source) |
| Nov 2, 2026 | Copper peptide serum | Said FDA listed GHK-Cu as a significant safety risk. Injectable GHK-Cu sat in category 2 until its nomination was withdrawn in April 2026; the page now gives that history. (source) |
| Nov 2, 2026 | Tirzepatide | Corrected the date FDA's compounding enforcement for tirzepatide ended under 503A (March 5, 2025) and the date of Mounjaro's pediatric type 2 diabetes indication (December 2025). Removed a statement that tirzepatide was not studied in people with past pancreatitis, which the current label no longer says. (source) |
| Nov 2, 2026 | Where to inject peptides | Said every injectable peptide drug uses the same three sites. The Egrifta (tesamorelin) labels specify the abdomen only; the page now lists sites label by label. (source) |
| Nov 2, 2026 | AOD-9604 | Described the main phase 2b trial as 12 weeks of treatment; it ran 24 weeks. The peptide is 16 amino acids long (a 15-amino-acid growth hormone fragment plus an added tyrosine), which the page now states with FDA's wording. (source) |
| Nov 2, 2026 | BPC-157 | Evidence level said 'Animal studies only' and that no controlled human trials exist. FDA's review lists five small human studies, including placebo-controlled work published only as meeting abstracts, which FDA found inadequate to show benefit or safety. Evidence level corrected to 'Early human studies' on the hub, dosage and side-effects pages. (source) |
| Oct 25, 2026 | Tirzepatide cost | Self-pay prices after a missed 45-day refill window corrected from $849 (12.5 mg) and $1,049 (15 mg) to $699, matching LillyDirect's current pricing. Added Mounjaro's $499 self-pay price. (source) |
| Oct 25, 2026 | Peptides A–Z | SS-31 (elamipretide) was listed as investigational. It received FDA accelerated approval as Forzinity on Sept 19, 2025 for Barth syndrome; status corrected to FDA approved. (source) |
| Oct 25, 2026 | Tirzepatide dosage chart | Said every Zepbound pen and vial delivers 0.5 mL. That is true of single-dose pens and vials only; the KwikPen and multi-dose vials on the August 2026 label deliver 0.6 mL per dose. (source) |
| Oct 25, 2026 | Peptides A–Z | AOD-9604 was described as hGH fragment 176-191. FDA's December 2024 briefing describes it as tyrosine plus hGH 177-191 (16 amino acids); the note now says so. (source) |